TFF PHARMACEUTICALS, INC.
BioSniper Score
Based on 4 of 6 signals
Market Cap
—
Cash Runway
4.4 mo
Lead Asset
tff tac (Phase 2)
Next Catalyst
—
Tracking 2 pipeline candidates for TFF PHARMACEUTICALS, INC. · Updated within the last hour.
Go deeper on TFF PHARMACEUTICALS, INC. with Spotter
Ask follow-up questions and run a full multi-agent deep dive on TFFP — live, with citations.
Score breakdownBased on 4 of 6 signals · derived from public data
4.4 months
D/E 1.26 · 24% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Key Financialsas of September 30, 2024
Cash
$2.6M
Quarterly Burn
$2.0M
Revenue
$193K
Free Cash Flow
-$2.0M
Total Liabilities
$3.9M
Shareholders Equity
$3.1M
Current Ratio
0.89
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Commercialization & Governance
Commercialization
- Status
- Clinical-stage
- Has Revenue
- No
Frequently asked questions
What is TFF PHARMACEUTICALS, INC.'s lead drug candidate?
TFF PHARMACEUTICALS, INC.'s most advanced tracked candidate is tff tac (Phase 2) for prophylaxis of organ rejection in patients receiving lung transplants.
Who is the CEO of TFF PHARMACEUTICALS, INC.?
Craig Jalbert is the chief executive officer of TFF PHARMACEUTICALS, INC. (TFFP).
What therapeutic areas does TFF PHARMACEUTICALS, INC. focus on?
TFF PHARMACEUTICALS, INC. develops therapies across Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on TFF PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.